To observe the mild inflammation status and the expression of FGF23 in patients with uremia and Bailing capsule’s impact on it.Methods:Totally 100 cases of patients with uremia in our hospital were included into the study, randomly divided into the control group and the observation group. And 50 cases of healthy check-up in the same period were the healthy group. The clinical biochemical index, CRP, FGF23 levels changes of the three groups were observed. Results:1) Before the treatment, mean arterial pressure, BUN, SCr and EsR levels of the uremic patients increased significantly comparing to the healthy and control groups (P<0.05), erythrocyte, hemoglobin and transferrin significantly lower than healthy and controls groups (P<0.05). And the above indexes were with no statistically significant difference between the two groups of patients with uremia (P>0.05). After a period of treatment, the clinical biochemical indicators of patients in the two groups had different degrees of improvement. The observation group, which took Bailing capsules, had more obvious improvement than the control group, and the differences were statistically significant (P<0.05); 2) The IL-6 and FGF23 level of both groups before treatment were higher than normal levels, and both of the 2 levels decreased after treatment, but the downward trend of Bailing capsule group was more obvious. 3) The relationship between the concentration of FGF23 and IL-6 levels had positive correlation (r=0.242, P<0.01). FGF23 and ALB and HDL levels had negative correlation (r1=-0.342 P<0.01) and (r=-0.425, P<0.01) .Conclusion:The expression level of peripheral blood FGF and IL-6 in patients with uremia increased obviously; Bailing capsule may inhibit the expression of IL-6 to improve the status of inflammation in patients with uremia hemodialysis; FGF23 may become a new target for early diagnosis and intervention of inflammation in patients with uremia hemodialysis.